Family history of cancer in children and adolescents with germ cell tumours: a report from the Children’s Oncology Group

Poynter, Jenny N.; Richardson, Michaela; Roesler, Michelle A.; Krailo, Mark; Amatruda, James F.; Frazier, A. Lindsay

doi:10.1038/bjc.2017.358

Cited by 8 publications

(6 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In fact, several investigators have successfully leveraged CCRN for etiologic studies of several childhood cancers. [6][7][8][9][10][11][12] Despite these accomplishments, however, questions remain about the overall representativeness of the resource.…”

Section: Introductionmentioning

confidence: 99%

An updated assessment of 43,110 patients enrolled in the Childhood Cancer Research Network: A Children's Oncology Group report

Brown

Sok

Scheurer

et al. 2022

Cancer

View full text Add to dashboard Cite

Background The Childhood Cancer Research Network (CCRN) was established by the Children's Oncology Group (COG) as a resource for epidemiologic studies of childhood cancer. The objective of this study was to evaluate the representativeness of CCRN and identify factors associated with enrollment. Method The number of US childhood patients with cancer diagnosed <20 years of age enrolled in CCRN (2008‐2015) was compared to expected counts, calculated from Surveillance, Epidemiology, and End Results incidence rates and US Census population estimates. Observed‐to‐expected ratios and corresponding 95% confidence intervals (CI) were estimated across sex, race, diagnosis age, calendar year, and cancer diagnosis groups. Multivariable linear regression models were generated to evaluate the association between open COG phase 3 therapeutic trials and CCRN enrollment rates. Result The 43,110 cases enrolled in CCRN represented 36% of the expected childhood cancers diagnosed from 2008 to 2015 (N = 120,118). CCRN enrollment ratios [95% CI] were highest among males (0.38 [95% CI, 0.37‐0.38]), non‐Hispanics (0.35 [95% CI, 0.35‐0.36]), and those diagnosed from 1 to 4 years of age (0.50 [95% CI, 0.50‐51]). Enrollment ratios varied by diagnosis group, with leukemia, myeloproliferative diseases, myelodysplastic diseases (0.55 [95% CI, 0.54‐0.55]), and renal tumors (0.55 [95% CI, 0.53‐0.58]) having the highest enrollment. After adjusting for year of diagnosis and cancer diagnosis, there was a 3.1% [95% CI, 0.6‐5.6%] increase in CCRN enrollment during windows of open COG therapeutic trials. Conclusions Despite enrolling only 36% of newly diagnosed cases, CCRN remains a valuable resource for investigators conducting childhood cancer etiology and survivorship research. The results of this study may inform efforts to improve enrollment on current and future COG nontherapeutic registry protocols.

show abstract

Section: Introductionmentioning

confidence: 99%

An updated assessment of 43,110 patients enrolled in the Childhood Cancer Research Network: A Children's Oncology Group report

Brown

Sok

Scheurer

et al. 2022

Cancer

View full text Add to dashboard Cite

show abstract

“…Thirdly, for those with family history, AA homozygotes presented low susceptibility of cancer in our meta-analysis. Impact of family history on cancer occurrence and clinical features has been found in different types of cancer, and family history may also exert an influence on cancer through interaction with gene polymorphism [ 61 – 63 ]. In Mao et al’s meta-analysis [ 11 ], subgroup analysis was also performed by family history, but their results are not similar to ours.…”

Section: Discussionmentioning

confidence: 99%

Association between ATM rs1801516 polymorphism and cancer susceptibility: a meta-analysis involving 12,879 cases and 18,054 controls

Shi

Qiu

et al. 2018

BMC Cancer

View full text Add to dashboard Cite

BackgroundAtaxia telangiectasia mutated (ATM) gene plays a key role in response to DNA lesions and is related to the invasion and metastasis of malignancy. Epidemiological studies have indicated associations between ATM rs1801516 polymorphism and different types of cancer, but their results are inconsistent. To further evaluate the effect of ATM rs1801516 polymorphism on cancer risk, we conducted this meta-analysis.MethodsStudies were identified according to specific inclusion criteria by searching PubMed, Web of Science, and Embase databases. Pooled odds ratios (ORs) and corresponding 95% confidence intervals (CIs) under recessive, dominant, codominant, and overdominant models of inheritance were calculated to estimate the association between rs1801516 polymorphism and cancer risk.ResultsA total of 37 studies with 12,879 cases and 18,054 controls were included in our study. No significant association was found between rs1801516 polymorphism and cancer risk in overall comparisons (AA vs GG + GA: OR = 0.91, 95% CI, 0.78–1.07; AA+GA vs GG: OR = 1.00, 95% CI, 0.90–1.11; AA vs GG: OR = 0.89, 95% CI, 0.75–1.06; GA vs GG: OR = 1.01, 95% CI, 0.91–1.13; GG + AA vs GA: OR = 1.00, 95% CI, 0.88–1.10). However, after subgroup analyses by region-specified population, significant associations were found in European (AA vs GG + GA: OR = 0.79, 95% CI, 0.65–0.96, P = 0.017; AA vs GG: OR = 0.79, 95% CI, 0.65–0.96, P = 0.017), South American (AA+GA vs GG: OR = 2.15, 95% CI, 1.37–3.38, P = 0.001; GA vs GG: OR = 2.19, 95% CI, 1.38–3.47, P = 0.001; GG + AA vs GA: OR = 0.46, 95% CI, 0.29–0.72, P = 0.001), and Asian (AA vs GG + GA: OR = 7.45, 95% CI, 1.31–42.46, P = 0.024; AA vs GG: OR = 7.40, 95% CI, 1.30–42.19, P = 0.024). Subgroup analyses also revealed that compared with subjects carrying a GG genotype, those carrying a homozygote AA had a decreased risk for breast cancer (AA vs GG: OR = 0.76, 95% CI, 0.59–0.98, P = 0.035), and the homozygote AA was associated with decreased cancer risk in subjects with family history (AA vs GG: OR = 0.68, 95% CI, 0.47–0.98, P = 0.039).ConclusionsATM rs1801516 polymorphism is not associated with overall cancer risk in total population. However, for subgroup analyses, this polymorphism is especially associated with breast cancer risk; in addition, it is associated with overall cancer risk in Europeans, South Americans, Asians, and those with family history.Electronic supplementary materialThe online version of this article (10.1186/s12885-018-4941-1) contains supplementary material, which is available to authorized users.

show abstract

“…Given the paucity of molecular and epidemiologic data for GCT, the data from the GaMETES study have made a large contribution to understanding of disease etiology. Family history data collected from mothers and fathers of affected GCT cases were used to evaluate heritability of pediatric GCT, and showed a higher than expected number of GCT cases in both male and female relatives of cases 12 . The data were used to identify common variants that increase risk of developing GCT, and provided evidence of overlapping genetic susceptibility to pediatric and adult GCT 13 .…”

Section: Key Achievementsmentioning

confidence: 99%

“…Family history data collected from mothers and fathers of affected GCT cases were used to evaluate heritability of pediatric GCT, and showed a higher than expected number of GCT cases in both male and female relatives of cases. 12 The data were used to identify common variants that increase risk of developing GCT, and provided evidence of overlapping genetic susceptibility to pediatric and adult GCT. 13 We also quantified the association between Klinefelter syndrome and risk of GCT, 14 evaluated the role of predicted leukocyte telomere length in GCT risk, 15 and reported on the higher prevalence of birth defects in GCT cases.…”

Section: Germ Cell Tumorsmentioning

confidence: 99%

Children's Oncology Group's 2023 blueprint for research: Epidemiology

Lupo

Marcotte

Scheurer

et al. 2023

Pediatric Blood & Cancer

View full text Add to dashboard Cite

The Children's Oncology Group (COG) Epidemiology Committee has a primary focus on better understanding the etiologies of childhood cancers. Over the past 10 years, the committee has leveraged the Childhood Cancer Research Network, and now more recently Project:EveryChild (PEC), to conduct epidemiologic assessments of various childhood cancers, including osteosarcoma, neuroblastoma, germ cell tumors, Ewing sarcoma, rhabdomyosarcoma, and Langerhans cell histiocytosis. More recent studies have utilized questionnaire data collected as part of PEC to focus on specific characteristics and/or features, including the presence of congenital disorders and the availability of stored cord blood. Members of the COG Epidemiology Committee have also been involved in other large‐scale National Institutes of Health efforts, including the Childhood Cancer Data Initiative and the Gabriella Miller Kids First Pediatric Research Program, which are improving our understanding of the factors associated with childhood cancer risk. Future plans will focus on addressing questions surrounding health disparities, utilizing novel biospecimens in COG epidemiology studies, exploring the role of environmental factors on the etiologies and outcomes of childhood cancer, collaborating with other COG committees to expand the role of epidemiology in childhood cancer research, and building new epidemiologic studies from the Molecular Characterization Initiative—all with the ultimate goal of developing novel prevention and intervention strategies for childhood cancer.

show abstract

Family history of cancer in children and adolescents with germ cell tumours: a report from the Children’s Oncology Group

Abstract: These results support the hypothesis that familial aggregation of GCT occurs in males and females.

Cited by 8 publications

References 36 publications

An updated assessment of 43,110 patients enrolled in the Childhood Cancer Research Network: A Children's Oncology Group report

An updated assessment of 43,110 patients enrolled in the Childhood Cancer Research Network: A Children's Oncology Group report

Association between ATM rs1801516 polymorphism and cancer susceptibility: a meta-analysis involving 12,879 cases and 18,054 controls

Children's Oncology Group's 2023 blueprint for research: Epidemiology

Contact Info

Product

Resources

About